Literature DB >> 16893310

Aberrant drug-taking behaviors and headache: patient versus physician report.

Michael F Weaver1, Dale S Bond, Brent L Arnold, Elizabeth Waterhouse, Alan Towne.   

Abstract

OBJECTIVE: To explore prevalence of aberrant medication-taking behaviors (AMTB) among headache patients and treating physician's awareness of such behaviors.
METHODS: Fifty patientphysician dyads were surveyed on patients' AMTB.
RESULTS: The most frequently endorsed behaviors by patients and physicians, respectively, were going to the ER for pain medication (n = 19) and continuing to take pain medication despite minimal relief (n = 23). For the majority of AMTB, phi coefficients indicating level of patient-physician agreement were equal to chance.
CONCLUSIONS: Headache patients perform a wide range of AMTB. Low rates of patient-physician agreement indicate that physicians possess limited knowledge of patients' AMTB.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16893310     DOI: 10.5555/ajhb.2006.30.5.475

Source DB:  PubMed          Journal:  Am J Health Behav        ISSN: 1087-3244


  3 in total

1.  Aberrant drug-related behaviors: unsystematic documentation does not identify prescription drug use disorder.

Authors:  Ellen C Meltzer; Dennis Rybin; Lidia Z Meshesha; Richard Saitz; Jeffrey H Samet; Sonia L Rubens; Jane M Liebschutz
Journal:  Pain Med       Date:  2012-10-11       Impact factor: 3.750

2.  Aberrant behaviors with prescription opioids and problem drug use history in a community-based cohort of HIV-infected individuals.

Authors:  Luke Hansen; Joanne Penko; David Guzman; David R Bangsberg; Christine Miaskowski; Margot B Kushel
Journal:  J Pain Symptom Manage       Date:  2011-07-30       Impact factor: 3.612

3.  Patient vs provider reports of aberrant medication-taking behavior among opioid-treated patients with chronic pain who report misusing opioid medication.

Authors:  Valentina Nikulina; Honoria Guarino; Michelle C Acosta; Lisa A Marsch; Cassandra Syckes; Sarah K Moore; Russell K Portenoy; Ricardo A Cruciani; Dennis C Turk; Andrew Rosenblum
Journal:  Pain       Date:  2016-08       Impact factor: 7.926

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.